Skip to main content

Table 3 Associations between genetic risk scores and TNFi treatment response (achieving good/moderate EULAR response vs no) in overall RA, as well as in ACPA-positive RA and ACPA-negative RA

From: A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study

GRS Overall RA ACPA-positive RA ACPA-negative RA
GRS76SNPs
 Linear 0.96 (0.81–1.14) 1.00 (0.82–1.22) 0.89 (0.56–1.42)
 Q1 Reference Reference Reference
 Q2 vs Q1 0.68 (0.31–1.50) 1.00 (0.36–2.81) 0.66 (0.17–2.54)
 Q3 vs Q1 0.77 (0.37–1.60) 1.07 (0.42–2.71) 0.60 (0.15–2.36)
 Q4 vs Q1 0.79 (0.39–1.57) 1.06 (0.44–2.55) 0.95 (0.23–3.93)
GRSHaplotype
 Linear 0.92 (0.77–1.12) 0.96 (0.76–1.20) 1.30 (0.80–2.12)
 Q1 Reference Reference Reference
 Q2 vs Q1 1.15 (0.51–2.61) 0.76 (0.22–2.65) 2.35 (0.67–8.20)
 Q3 vs Q1 1.05 (0.52–2.12) 0.89 (0.30–2.65) 2.19 (0.58–8.30)
 Q4 vs Q1 0.99 (0.48–2.02) 0.84 (0.27–2.54) 3.53 (0.88–14.22)
 Any SE 0.79 (0.59–1.06) 0.84 (0.59–1.20) 1.07 (0.53–2.17)
  1. Data presented as odds ratio (95% confidence interval)
  2. ACPA anti-citrullinated protein/peptide antibodies, GRS genetic risk score, RA rheumatoid arthritis, Q quartile, SE shard epitope, TNFi tumor necrosis factor inhibitor, EULAR European League Against Rheumatism